[The effect of thyrotrophin releasing hormone versus placebo in combination with basic imipramine therapy of depressive patients].
20 female and 10 male patients with a retarded-depressive syndrome received imipramine (3 X 50 mg/day) for 20 days. In a double blind study oral thyrotrophin releasing hormone (TRH) (2 X 40 mg/day) and placebo, respectively, were added for the first 2 weeks. The patients were rated with the Hamiltion-depression scale and a selfrating depression scale. But the statistical evaluation showed no difference between the imipramine/TRH and the imipramine/placebo group.
D000328:Adult; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D013973:Thyrotropin-Releasing Hormone / Q000627:therapeutic use*
D010919:Placebos; D013973:Thyrotropin-Releasing Hormone; D007099:Imipramine
Wirkung von Thyreotropin Releasing Hormon im Vergleich zu Plazebo bei mit Imipramin behandelten depressiven Patienten